3-Cyano-N-(3-Cyano-4-Methyl-1H-Indol-7-Yl)Benzenesulfonamide 3-氰基-N-(3-氰基-4-甲基-1H-吲哚-7-基)苯磺酰胺
CAS 289483-69-8 MFCD89483698
化学结构图
SMILES: Cc1ccc(NS(=O)(=O)c2cccc(C#N)c2)c2[nH]cc(C#N)c12
化学属性
| Mol. Weight | 336.37 |
|---|---|
| Appearance | Solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name | 3-Cyano-N-(3-Cyano-4-Methyl-1H-Indol-7-Yl)Benzenesulfonamide |
|---|---|
| Formula | C17H12N4O2S |
| Synonym | E7820; E-7820; E 7820. |
| IUPAC Name | N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide |
| InChIKey | LWGUASZLXHYWIV-UHFFFAOYSA-N |
| InChI | InChI=1S/C17H12N4O2S/c1-11-5-6-15(17-16(11)13(9-19)10-20-17)21-24(22,23)14-4-2-3-12(7-14)8-18/h2-7,10,20-21H,1H3 |
| Canonical SMILES | O=S(C1=CC=CC(C#N)=C1)(NC2=CC=C(C)C3=C2NC=C3C#N)=O |
| Chemical Name Translation | 3-氰基-N-(3-氰基-4-甲基-1H-吲哚-7-基)苯磺酰胺 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- E7820 is a small molecule and aromatic sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
相关文献及参考
- [2]. Ito K, et al. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Cancer Sci. 2014;105(8):1023-1031.
- [1]. Funahashi Y, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res. 2002;62(21):6116-6123.
- [1]. Funahashi Y, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res. 2002;62(21):6116-6123.
- [2]. Ito K, et al. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Cancer Sci. 2014;105(8):1023-1031.
